SeekingAlpha.com reported that Eli Lilly had reached an agreement to acquire AtaiBeckley for $6.75 per share in upfront cash, with a potential additional payment of up to $2.50 per share contingent on meeting certain milestones. The deal was valued at approximately $2.8 billion [1].
Money.usnews.com provided more details about the acquisition, stating that Eli Lilly would pay up to $3.8 billion for AtaiBeckley, a move that places the company in a race with other pharmaceutical giants to develop psychedelic treatments for mental health conditions such as depression [2]. Both sources highlight the significant financial stakes involved in this deal.